Macular telangiectasia Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | OXURION, Neurotech Pharmaceuticals

Macular telangiectasia Pipeline constitutes 4+ key companies continuously working towards developing 4+ Macular telangiectasia treatment therapies, analyzes DelveInsight.

Macular telangiectasia Overview:

Macular Telangiectasia (MacTel) is a condition that impacts the macula, leading to a loss of central vision. It occurs due to issues with the tiny blood vessels around the fovea. There are two types of MacTel: Type 1 and Type 2. In Type 1 MacTel, blood vessels become dilated, leading to small aneurysms that cause swelling and damage to macular cells. This form typically affects one eye. Type 2 MacTel, the more common form, involves dilation and leakage of the capillaries around the fovea. This results in fluid buildup and swelling, impairing light reflection and causing progressive vision loss. As the damage progresses, new blood vessels may form, break, and leak, leading to scar tissue that further disrupts central vision. Type 2 MacTel typically affects both eyes and is most common in middle-aged adults.

Download our report @ https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Macular telangiectasia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Macular telangiectasia Therapeutics Market.

Key Takeaways from the Macular telangiectasia Pipeline Report

DelveInsight's Macular telangiectasia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Macular telangiectasia treatment.
In March 2025, the U.S. Food and Drug Administration (FDA) approved Encelto, a gene therapy implant developed by Neurotech Pharmaceuticals, for the treatment of MacTel. Encelto is the first FDA-approved therapy for this rare eye disease, marking a significant milestone in ophthalmology. ​
Key Macular telangiectasia companies such as OXURION, Neurotech Pharmaceuticals, and others are evaluating new drugs for Macular telangiectasia to improve the treatment landscape.
Promising Macular telangiectasia pipeline therapies in various stages of development include NT-501, THR 317, and others.

Macular telangiectasia Pipeline Analysis
The Macular telangiectasia pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Macular telangiectasia Market.

Categorizes Macular telangiectasia therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Macular telangiectasia drugs under development based on:

Stage of development

Macular telangiectasia Route of administration

Target receptor

Monotherapy vs. combination therapy

Macular telangiectasia Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Macular telangiectasia Licensing agreements

Funding and investment activities supporting future Macular telangiectasia market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Macular telangiectasia Emerging Drugs

NT-501: Neurotech Pharmaceuticals

NT-501 (Renexus) is an encapsulated cell therapy designed to treat Macular Telangiectasia (MacTel). Currently, it is being tested in a Phase 3, randomized, multi-center trial to assess the safety and efficacy of Renexus implants in individuals with Type 2 MacTel. NT-501 is an innovative cell-based drug delivery system, where human-derived cells are encapsulated in a semipermeable hollow fiber membrane device to release ciliary neurotrophic factor (CNTF). In July 2012, NT-501 received orphan drug status for MacTel type 2 from the FDA, and in February 2019, it was granted Fast Track designation for this indication.

THR 317: OXURION

THR-317 is an inhibitor of Placenta Growth Factor (PlGF) and is currently being assessed in a Phase II trial for the treatment of Idiopathic Macular Telangiectasia (MacTel) Type 1.

Macular telangiectasia Companies

There are about 4+ major companies working on therapies for Macular Telangiectasia (MacTel). Neurotech Pharmaceuticals is one of the companies with MacTel drug candidates in the most advanced stage, currently in Phase III.

DelveInsight's report covers around 4+ products under different phases of Macular telangiectasia clinical trials like

Macular telangiectasia Late stage Therapies (Phase III)
Macular telangiectasia Mid-stage Therapies (Phase II)
Macular telangiectasia Early-stage Therapies (Phase I)
Macular telangiectasia Pre-clinical and Macular telangiectasia Discovery stage Therapies
Macular telangiectasia Discontinued & Inactive Therapies

Macular telangiectasia pipeline report provides the Macular telangiectasia therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Macular telangiectasia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Macular telangiectasia Therapies and Key Macular telangiectasia Companies: Macular telangiectasia Clinical Trials and recent advancements https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Macular telangiectasia Pipeline Therapeutic Assessment
• Macular telangiectasia Assessment by Product Type
• Macular telangiectasia By Stage
• Macular telangiectasia Assessment by Route of Administration
• Macular telangiectasia Assessment by Molecule Type

Download Macular telangiectasia Sample report to know in detail about the Macular telangiectasia treatment market @ Macular telangiectasia Therapeutic Assessment https://www.delveinsight.com/sample-request/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Macular telangiectasia Current Treatment Patterns
4. Macular telangiectasia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Macular telangiectasia Late-Stage Products (Phase-III)
7. Macular telangiectasia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Macular telangiectasia Discontinued Products
13. Macular telangiectasia Product Profiles
14. Macular telangiectasia Key Companies
15. Macular telangiectasia Key Products
16. Dormant and Discontinued Products
17. Macular telangiectasia Unmet Needs
18. Macular telangiectasia Future Perspectives
19. Macular telangiectasia Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Macular telangiectasia Pipeline Reports Offerings: https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.